ATE375347T1 - Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung - Google Patents
Pyrazolopyrimidinonderivate mit pde7-hemmender wirkungInfo
- Publication number
- ATE375347T1 ATE375347T1 AT02788833T AT02788833T ATE375347T1 AT E375347 T1 ATE375347 T1 AT E375347T1 AT 02788833 T AT02788833 T AT 02788833T AT 02788833 T AT02788833 T AT 02788833T AT E375347 T1 ATE375347 T1 AT E375347T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibiting effect
- pyrazolopyrimidinone derivatives
- pde7
- chem
- general formula
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 title abstract 2
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001380483 | 2001-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375347T1 true ATE375347T1 (de) | 2007-10-15 |
Family
ID=19187176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02788833T ATE375347T1 (de) | 2001-12-13 | 2002-12-13 | Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7268128B2 (de) |
| EP (1) | EP1454897B1 (de) |
| JP (1) | JP4312603B2 (de) |
| KR (1) | KR100929513B1 (de) |
| CN (1) | CN1264843C (de) |
| AT (1) | ATE375347T1 (de) |
| BR (2) | BRPI0207215B8 (de) |
| CA (1) | CA2439784C (de) |
| DE (1) | DE60222931T2 (de) |
| ES (1) | ES2294189T3 (de) |
| HU (1) | HU228316B1 (de) |
| WO (1) | WO2003053975A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| DE102004027871B3 (de) * | 2004-06-08 | 2006-03-16 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von 10α-[4'-(S,S-Dioxothiomorpholin-1'-yl)]-10-desoxo-10-dihydroartemisinin |
| PT1775298E (pt) * | 2004-07-01 | 2013-06-12 | Daiichi Sankyo Co Ltd | Derivado de tienopirazol com atividade inibidora da pde 7 |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| TW200745106A (en) * | 2005-10-03 | 2007-12-16 | Astrazeneca Ab | Chemical compounds |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| CN1966506A (zh) * | 2005-11-17 | 2007-05-23 | 上海特化医药科技有限公司 | 吡唑并嘧啶酮衍生物及其制备方法和用途 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2662491A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20090137549A1 (en) * | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| US20080242661A1 (en) * | 2006-12-11 | 2008-10-02 | Graeme James Dykes | Novel compounds useful for the treatment of degenerative & inflammatory diseases |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| NZ580413A (en) | 2007-03-27 | 2012-11-30 | Omeros Corp | The use of pde7 inhibitors for the treatment of movement disorders |
| US20100305113A1 (en) * | 2007-05-09 | 2010-12-02 | Hans-Georg Capraro | Substituted Imidazopyridazines as Lipid Kinase Inhibitors |
| CN102131811A (zh) | 2008-06-24 | 2011-07-20 | 财团法人乙卯研究所 | 具有稠合环的*唑烷酮衍生物 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| MX2013004943A (es) | 2010-11-08 | 2013-09-02 | Omeros Corp | Tratamiento de trastornos de adicion y control de impulsos usando inhibidores de pde7. |
| CN102134242B (zh) * | 2011-01-21 | 2013-08-28 | 浙江大德药业集团有限公司 | 一种用于治疗阳痿的快速长效的化合物 |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| JP6986972B2 (ja) | 2015-06-18 | 2021-12-22 | エイティナイン バイオ リミテッド | 置換4−ベンジル及び4−ベンゾイルピペリジン誘導体 |
| KR20180026459A (ko) | 2015-06-18 | 2018-03-12 | 세파론, 인코포레이티드 | 1,4-치환된 피페리딘 유도체 |
| WO2017059191A1 (en) * | 2015-09-30 | 2017-04-06 | Quartet Medicine, Inc. | Heteroaryl derivatives as sepiapterin reductase inhibitors |
| WO2018125810A1 (en) | 2016-12-28 | 2018-07-05 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| CN111655695B (zh) | 2017-11-27 | 2025-05-27 | 达特神经科学有限公司 | 作为pde1抑制剂的取代的呋喃并嘧啶化合物 |
| CA3264002A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITING ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB9315017D0 (en) * | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| GB9423911D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| DE19501480A1 (de) * | 1995-01-19 | 1996-07-25 | Bayer Ag | 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one |
| JP3713783B2 (ja) | 1995-01-20 | 2005-11-09 | 大正製薬株式会社 | 1H−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体 |
| US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| AU4589800A (en) * | 1999-05-05 | 2000-11-21 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors |
| DE19950647A1 (de) * | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
| DE19953025A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
| DE19953414A1 (de) * | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
-
2002
- 2002-12-13 CA CA2439784A patent/CA2439784C/en not_active Expired - Lifetime
- 2002-12-13 AT AT02788833T patent/ATE375347T1/de not_active IP Right Cessation
- 2002-12-13 CN CNB02809154XA patent/CN1264843C/zh not_active Expired - Lifetime
- 2002-12-13 BR BRPI0207215A patent/BRPI0207215B8/pt active IP Right Grant
- 2002-12-13 BR BR0207215-7A patent/BR0207215A/pt active IP Right Grant
- 2002-12-13 JP JP2003554691A patent/JP4312603B2/ja not_active Expired - Lifetime
- 2002-12-13 WO PCT/JP2002/013083 patent/WO2003053975A1/ja not_active Ceased
- 2002-12-13 EP EP02788833A patent/EP1454897B1/de not_active Expired - Lifetime
- 2002-12-13 DE DE60222931T patent/DE60222931T2/de not_active Expired - Lifetime
- 2002-12-13 HU HU0402171A patent/HU228316B1/hu unknown
- 2002-12-13 ES ES02788833T patent/ES2294189T3/es not_active Expired - Lifetime
- 2002-12-13 KR KR1020037012495A patent/KR100929513B1/ko not_active Expired - Lifetime
-
2004
- 2004-06-14 US US10/866,198 patent/US7268128B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2439784A1 (en) | 2003-07-03 |
| DE60222931T2 (de) | 2008-07-10 |
| DE60222931D1 (de) | 2007-11-22 |
| ES2294189T3 (es) | 2008-04-01 |
| KR20040065156A (ko) | 2004-07-21 |
| BRPI0207215B1 (pt) | 2003-07-03 |
| JP4312603B2 (ja) | 2009-08-12 |
| EP1454897A4 (de) | 2005-11-23 |
| CA2439784C (en) | 2010-11-02 |
| US20050148604A1 (en) | 2005-07-07 |
| HUP0402171A3 (en) | 2008-08-28 |
| EP1454897A1 (de) | 2004-09-08 |
| HU228316B1 (en) | 2013-03-28 |
| US7268128B2 (en) | 2007-09-11 |
| CN1533392A (zh) | 2004-09-29 |
| KR100929513B1 (ko) | 2009-12-03 |
| HUP0402171A2 (hu) | 2005-02-28 |
| EP1454897B1 (de) | 2007-10-10 |
| WO2003053975A1 (en) | 2003-07-03 |
| CN1264843C (zh) | 2006-07-19 |
| BR0207215A (pt) | 2004-02-10 |
| JPWO2003053975A1 (ja) | 2005-04-28 |
| BRPI0207215B8 (pt) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE375347T1 (de) | Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung | |
| DK0842934T3 (da) | 5-HT1F agonister | |
| CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
| TR200101499T1 (tr) | Azepinoindol türevleri, hazırlanmaları ve kullanımları. | |
| WO2003006425A3 (en) | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
| NO20054404L (no) | 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon | |
| EP1767197A3 (de) | Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit | |
| WO2004014893A3 (en) | Antimicrobial aza-bicyclic derivates, their compositions and uses | |
| EP2025679A3 (de) | [3,2,0]-Heterocyclische Verbindungen und Verfahren zu Ihrer Verwendung | |
| AU1182702A (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
| DK1313740T3 (da) | Prodrugs af imidazopyridinderivater | |
| ATE457977T1 (de) | Biguanidderivate | |
| ATE449066T1 (de) | Biguanidderivate | |
| DK0916670T3 (da) | Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister | |
| WO2005018627A8 (en) | Alpha-aminoamide derivatives useful as anti-inflammatory agents | |
| BR0206922A (pt) | Compostos orgânicos | |
| BR0316996B1 (pt) | Derivados de 1-aril-3-amidoxima-pirazol pesticida | |
| DE60318033D1 (de) | Biguanid-derivate und deren verwendung als antidiabetika | |
| DK1499312T3 (da) | Anvendelse af hydroxypyridonderivater til sårheling | |
| DE60236729D1 (de) | Aroma- und duftstoffzusammensetzungen | |
| WO2004056762A3 (en) | Novel aminobenzophenone compounds | |
| ATE549925T1 (de) | Herbizide mittel enthaltend 3- aminobenzoylpyrazole und safener | |
| WO2005054284A3 (en) | Regulation involving abin-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |